{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:32Z","timestamp":1787878232640,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Overactive bladder (OAB) is a prevalent and potentially debilitating syndrome that significantly impairs quality of life. Mirabegron and vibegron are \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      -adrenoceptor (\u03b2\n                      <jats:sub>3<\/jats:sub>\n                      AR) agonists that provide a different mechanism of action to antimuscarinic medications. Vibegron has high \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      AR selectivity and enhances detrusor relaxation without compromising voiding function. This review summarises the clinical and real-world evidence supporting the efficacy, safety and patient-reported benefits of vibegron in OAB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of the PubMed database was conducted in December 2024 using the keyword \"vibegron\". This search yielded 123 entries, which were subsequently screened by title for relevance to the objectives of this narrative review. All relevant articles identified through this process were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pivotal phase III trials have demonstrated significant reductions in urgency, urinary frequency and urgency urinary incontinence with vibegron, with rapid onset of action and a more favourable tolerability profile than antimuscarinics. The benefits of vibegron were consistent across diverse patient populations, including older adults and those with concomitant benign prostatic hyperplasia. Real-world data further suggest that vibegron is associated with improved adherence and persistence compared with other OAB therapies. Additionally, cardiovascular safety studies confirm that vibegron has no clinically significant effects on blood pressure or heart rate. While comparative trials with mirabegron indicate similar efficacy, vibegron\u2019s higher \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      AR selectivity and lack of cytochrome P450 interactions offer advantages in specific patient groups. Ongoing research, including real-world phase IV studies, aims to further define the long-term effectiveness and safety of vibegron in clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vibegron represents an important advance in the pharmacologic management of OAB, providing a well-tolerated and effective alternative to existing therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05799-8","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:18:35Z","timestamp":1756207115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes"],"prefix":"10.1007","volume":"43","author":[{"given":"Benoit","family":"Peyronnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"De Nunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Heesakkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-8467","authenticated-orcid":false,"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Serati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"5799_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167\u2013178. https:\/\/doi.org\/10.1002\/nau.10052","journal-title":"Neurourol Urodyn"},{"key":"5799_CR2","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","volume":"75","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet B, Mironska E, Chapple C et al (2019) A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol 75:988\u20131000. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.038","journal-title":"Eur Urol"},{"key":"5799_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108:1132\u20131138. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09993.x","journal-title":"BJU Int"},{"key":"5799_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L, Roberts RG, Th\u00fcroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02228.x","journal-title":"BJU Int"},{"key":"5799_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4","journal-title":"World J Urol"},{"key":"5799_CR6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","volume":"188","author":"EA Gormley","year":"2012","unstructured":"Gormley EA, Lightner DJ, Burgio KL et al (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. J Urol 188:2455\u20132463. https:\/\/doi.org\/10.1016\/j.juro.2012.09.079","journal-title":"J Urol"},{"key":"5799_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14656566.2020.1809652","volume":"22","author":"T Rechberger","year":"2021","unstructured":"Rechberger T, Wr\u00f3bel A (2021) Evaluating vibegron for the treatment of overactive bladder. Expert Opin Pharmacother 22:9\u201317. https:\/\/doi.org\/10.1080\/14656566.2020.1809652","journal-title":"Expert Opin Pharmacother"},{"key":"5799_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/rru.S387205","volume":"15","author":"R Mohamed-Ahmed","year":"2023","unstructured":"Mohamed-Ahmed R, Taithongchai A, da Silva AS, Robinson D, Cardozo L (2023) Treating and managing urinary incontinence: Evolving and potential multicomponent medical and lifestyle interventions. Res Rep Urol 15:193\u2013203. https:\/\/doi.org\/10.2147\/rru.S387205","journal-title":"Res Rep Urol"},{"key":"5799_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.urology.2023.11.021","volume":"184","author":"M Bowman","year":"2024","unstructured":"Bowman M, V\u00e9lez CA, Jericevic D et al (2024) Factors influencing medication selection for management of overactive bladder: trends and insights from AUA quality registry. Urology 184:51\u201357. https:\/\/doi.org\/10.1016\/j.urology.2023.11.021","journal-title":"Urology"},{"key":"5799_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/ju.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ et al (2024) The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol 212:11\u201320. https:\/\/doi.org\/10.1097\/ju.0000000000003985","journal-title":"J Urol"},{"key":"5799_CR11","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.clinthera.2013.08.017","volume":"35","author":"MB Chancellor","year":"2013","unstructured":"Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D (2013) Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 35:1744\u20131751. https:\/\/doi.org\/10.1016\/j.clinthera.2013.08.017","journal-title":"Clin Ther"},{"key":"5799_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J (2019) Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 179:1084\u20131093. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677","journal-title":"JAMA Intern Med"},{"key":"5799_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14740338.2019.1652269","volume":"18","author":"AE M\u00fcderrisoglu","year":"2019","unstructured":"M\u00fcderrisoglu AE, Becher KF, Madersbacher S, Michel MC (2019) Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf 18:915\u2013923. https:\/\/doi.org\/10.1080\/14740338.2019.1652269","journal-title":"Expert Opin Drug Saf"},{"key":"5799_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100674","volume":"96","author":"BM Brucker","year":"2022","unstructured":"Brucker BM, King J, Mudd PN Jr, McHale K (2022) Selectivity and maximum response of vibegron and mirabegron for \u03b2(3)-adrenergic receptors. Curr Ther Res Clin Exp 96:100674. https:\/\/doi.org\/10.1016\/j.curtheres.2022.100674","journal-title":"Curr Ther Res Clin Exp"},{"key":"5799_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2019-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642\u2013647. https:\/\/doi.org\/10.1124\/jpet.106.115840","journal-title":"J Pharmacol Exp Ther"},{"key":"5799_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple CR, Cruz F, Cardozo L et al (2020) Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol 77:119\u2013128. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.024","journal-title":"Eur Urol"},{"key":"5799_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","volume":"59","author":"SD Edmondson","year":"2016","unstructured":"Edmondson SD, Zhu C, Kar NF et al (2016) Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem 59:609\u2013623. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01372","journal-title":"J Med Chem"},{"key":"5799_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0022-5347(05)00067-4","volume":"175","author":"H Hashim","year":"2006","unstructured":"Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175:191\u2013194. https:\/\/doi.org\/10.1016\/s0022-5347(05)00067-4","journal-title":"J Urol"},{"key":"5799_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel MC, Cardozo L, Chermansky CJ et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev 75:554\u2013674. https:\/\/doi.org\/10.1124\/pharmrev.121.000523","journal-title":"Pharmacol Rev"},{"key":"5799_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cont.2024.101691","volume":"11","author":"C Chapple","year":"2024","unstructured":"Chapple C (2024) The sensory system is a target for pharmaceutical therapy of overactive bladder. Continence 11:101691. https:\/\/doi.org\/10.1016\/j.cont.2024.101691","journal-title":"Continence"},{"key":"5799_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2018.11.013","volume":"75","author":"CR Chapple","year":"2019","unstructured":"Chapple CR (2019) What is the current role of \u03b2(3)-adrenergic receptor agonists and how do they work? Eur Urol 75:283\u2013284. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.013","journal-title":"Eur Urol"},{"key":"5799_CR22","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bph.14658","volume":"176","author":"Y Igawa","year":"2019","unstructured":"Igawa Y, Aizawa N, Michel MC (2019) \u03b2(3) -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions? Br J Pharmacol 176:2525\u20132538. https:\/\/doi.org\/10.1111\/bph.14658","journal-title":"Br J Pharmacol"},{"key":"5799_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cpdd.1169","volume":"11","author":"J King","year":"2022","unstructured":"King J, Walker A, Aikin D, Haag-Molkenteller C, Kankam M (2022) Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults. Clin Pharmacol Drug Dev 11:1349\u20131355. https:\/\/doi.org\/10.1002\/cpdd.1169","journal-title":"Clin Pharmacol Drug Dev"},{"key":"5799_CR24","unstructured":"National Center for Biotechnology Information (2025) PubChem compound summary for CID 44472635, vibegron. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Vibegron. Accessed 12 March 2025"},{"key":"5799_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290685","volume":"18","author":"S Yamamoto","year":"2023","unstructured":"Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T (2023) Vibegron shows high selectivity and potent agonist activity for \u03b23-adrenoceptors, irrespective of receptor density. PLoS ONE 18:e0290685. https:\/\/doi.org\/10.1371\/journal.pone.0290685","journal-title":"PLoS ONE"},{"key":"5799_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.116.237313","volume":"360","author":"J Di Salvo","year":"2017","unstructured":"Di Salvo J, Nagabukuro H, Wickham LA et al (2017) Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther 360:346\u2013355. https:\/\/doi.org\/10.1124\/jpet.116.237313","journal-title":"J Pharmacol Exp Ther"},{"key":"5799_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s40265-018-1006-3","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ (2018) Vibegron: first global approval. Drugs 78:1835\u20131839. https:\/\/doi.org\/10.1007\/s40265-018-1006-3","journal-title":"Drugs"},{"key":"5799_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","volume":"75","author":"HD Mitcheson","year":"2019","unstructured":"Mitcheson HD, Samanta S, Muldowney K et al (2019) Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol 75:274\u2013282. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.006","journal-title":"Eur Urol"},{"key":"5799_CR29","doi-asserted-by":"publisher","first-page":"E970","DOI":"10.1016\/j.juro.2018.02.2331","volume":"199","author":"R Dmochowski","year":"2018","unstructured":"Dmochowski R, Mitcheson D, Frenkl T, Bennett N, Mudd PN (2018) Durable efficacy and safety of long-term once-daily vibegron, a novel oral \u03b2-3 adrenergic receptor agonist: a 52-week phase 2 study in patients with overactive bladder syndrome. J Urology 199:E970\u2013E971","journal-title":"J Urology"},{"key":"5799_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T (2018) Vibegron, a novel potent and selective \u03b2(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 73:783\u2013790. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.022","journal-title":"Eur Urol"},{"key":"5799_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/iju.13596","volume":"25","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T (2018) Long-term safety and efficacy of the novel \u03b2(3) -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int J Urol 25:668\u2013675. https:\/\/doi.org\/10.1111\/iju.13596","journal-title":"Int J Urol"},{"key":"5799_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/ju.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr (2020) International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204:316\u2013324. https:\/\/doi.org\/10.1097\/ju.0000000000000807","journal-title":"J Urol"},{"key":"5799_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12325-021-01972-8","volume":"39","author":"J Frankel","year":"2022","unstructured":"Frankel J, Staskin D, Varano S et al (2022) Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR. Adv Ther 39:959\u2013970. https:\/\/doi.org\/10.1007\/s12325-021-01972-8","journal-title":"Adv Ther"},{"key":"5799_CR34","doi-asserted-by":"publisher","first-page":"6475014","DOI":"10.1155\/2022\/6475014","volume":"2022","author":"D Staskin","year":"2022","unstructured":"Staskin D, Frankel J, Varano S et al (2022) Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial. Int J Clin Pract 2022:6475014. https:\/\/doi.org\/10.1155\/2022\/6475014","journal-title":"Int J Clin Pract"},{"key":"5799_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/spv.0000000000001258","volume":"29","author":"DK Newman","year":"2023","unstructured":"Newman DK, Thomas E, Greene H, Haag-Molkenteller C, Varano S (2023) Efficacy and safety of vibegron for the treatment of overactive bladder in women: a subgroup analysis from the double-blind, randomized, controlled EMPOWUR trial. Urogynecology (Phila) 29:48\u201357. https:\/\/doi.org\/10.1097\/spv.0000000000001258","journal-title":"Urogynecology (Phila)"},{"key":"5799_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40266-020-00829-z","volume":"38","author":"S Varano","year":"2021","unstructured":"Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr (2021) Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged \u226565 and \u226575 years: Subpopulation analysis from the EMPOWUR randomized, international, phase III study. Drugs Aging 38:137\u2013146. https:\/\/doi.org\/10.1007\/s40266-020-00829-z","journal-title":"Drugs Aging"},{"key":"5799_CR37","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/ju.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr (2021) Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol 205:1421\u20131429. https:\/\/doi.org\/10.1097\/ju.0000000000001574","journal-title":"J Urol"},{"key":"5799_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/ju.0000000000003999","volume":"212","author":"D Staskin","year":"2024","unstructured":"Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S (2024) Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol 212:256\u2013266. https:\/\/doi.org\/10.1097\/ju.0000000000003999","journal-title":"J Urol"},{"key":"5799_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/mbp.0000000000000572","volume":"27","author":"MA Weber","year":"2022","unstructured":"Weber MA, Haag-Molkenteller C, King J, Walker A, Mudd PN Jr, White WB (2022) Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Press Monit 27:128\u2013134. https:\/\/doi.org\/10.1097\/mbp.0000000000000572","journal-title":"Blood Press Monit"},{"key":"5799_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00345-024-04799-4","volume":"42","author":"N Wada","year":"2024","unstructured":"Wada N, Mizunaga M, Abe N et al (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42:113. https:\/\/doi.org\/10.1007\/s00345-024-04799-4","journal-title":"World J Urol"},{"key":"5799_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","volume":"175","author":"M Kinjo","year":"2023","unstructured":"Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H (2023) Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 175:67\u201373. https:\/\/doi.org\/10.1016\/j.urology.2023.02.003","journal-title":"Urology"},{"key":"5799_CR42","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/nau.25478","volume":"43","author":"B Chastek","year":"2024","unstructured":"Chastek B, Carrera A, Landis C et al (2024) Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: a retrospective claims study. Neurourol Urodyn 43:1504\u20131513. https:\/\/doi.org\/10.1002\/nau.25478","journal-title":"Neurourol Urodyn"},{"key":"5799_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00345-024-05025-x","volume":"42","author":"R Dai","year":"2024","unstructured":"Dai R, Deng C (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42:316. https:\/\/doi.org\/10.1007\/s00345-024-05025-x","journal-title":"World J Urol"},{"key":"5799_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12894-023-01240-7","volume":"23","author":"RR Dmochowski","year":"2023","unstructured":"Dmochowski RR, Rovner ES, Kennelly MJ et al (2023) Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder. BMC Urol 23:64. https:\/\/doi.org\/10.1186\/s12894-023-01240-7","journal-title":"BMC Urol"},{"key":"5799_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13256-020-02564-w","volume":"15","author":"T Kato","year":"2021","unstructured":"Kato T, Mizuno K, Nishio H, Yasui T, Hayashi Y (2021) Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report. J Med Case Rep 15:86. https:\/\/doi.org\/10.1186\/s13256-020-02564-w","journal-title":"J Med Case Rep"},{"key":"5799_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5980\/jpnjurol.114.81","volume":"114","author":"S Yamamoto","year":"2023","unstructured":"Yamamoto S, Hirano T, Nakamura C, Mori K, Hamano A (2023) Effects of combination therapy with vibegron for anticholinergic-resistant pediatric neurogenic bladder [in Japanese]. Nihon Hinyokika Gakkai Zasshi 114:81\u201385. https:\/\/doi.org\/10.5980\/jpnjurol.114.81","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"5799_CR47","unstructured":"European Medicines Agency (2024) Obgemsa 75 mg film-coated tablets. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/obgemsa-epar-product-information_en.pdf. Accessed 7 April 2025"},{"key":"5799_CR48","unstructured":"European Medicines Agency (2013) Betmiga 50 mg prolonged-release tablets. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/betmiga-epar-product-information_en.pdf. Accessed 7 April 2025"},{"key":"5799_CR49","unstructured":"United States Food and Drug Administration (2012) Myrbetriq prescribing information. https:\/\/www.astellas.com\/us\/system\/files\/Myrbetriq_WPI.pdf. Accessed 1 May 2025"},{"key":"5799_CR50","unstructured":"United States Food and Drug Administration (2020) Gemtesa prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213006s000lbl.pdf. Accessed 1 May 2025"}],"updated-by":[{"DOI":"10.1007\/s00345-025-06010-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000}}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05799-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:02:58Z","timestamp":1767996178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05799-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5799"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05799-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00345-025-06010-8","URL":"https:\/\/doi.org\/10.1007\/s00345-025-06010-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BP is a consultant for Boston Scientific, Medtronic, Intuitive, Pierre Fabre, IBSA, Coloplast, Convatec, schwa medico, Hollister, AbbVie, Ipsen. BMB is a speaker for AbbVie, Axonics and Sumitomo Pharma, an investigator for AbbVie and Provepharm, and an advisor for Sumitomo Pharma, AbbVie, Medtronic and Watkins Conti. CDN is a speaker and consultant for Pierre Fabre, Ipsen, Janssen, Bayer, Accord and Idipharma. CG has received grants\/research support from Astellas Pharma, Bayer, GSK, MSD and Recordati, and honoraria\/consultation fees from Amgen, Astellas Pharma, Bayer, GSK, Ipsen, Janssen, Lilly Pharma, Medac, Novartis, Pierre Fabre, Recordati, Pfizer, Rottapharm and STEBA Biotech. JH is an investigator, speaker and consultant for, and received grants from, Astellas, Pierre Fabre, Medtronic, BlueWind and Eli Lilly. MCM has received consultancy or lecturer honoraria in the field of functional urology from Apogepha, Astellas, Biohaven, Dr. Willmar Schwabe, MiP Pharma and Pierre Fabre. MS is a speaker and consultant for, and received grants from, Pierre Fabre, Laborie and Coloplast. DS is an investigator, advisor and speaker for Sumitomo Pharma America and a speaker for Pierre-Fabre Medicament. CC is a consultant and speaker for Pierre Fabre, consultant to Pelvisure, and past consultant and speaker during the development of many compounds used for the treatment of OAB. MS is a speaker and consultant for, and received grants from, Pierre Fabre, Laborie and Coloplast. DS is an investigator, advisor and speaker for Sumitomo Pharma America and a speaker for Pierre-Fabre Medicament. CC is a consultant and speaker for Pierre Fabre, consultant to Pelvisure, and past consultant and speaker during the development of many compounds used for the treatment of OAB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"514"}}